Abstract
Background: The present analysis was performed on data from a subsample of patients with schizoaffective disorder, bipolar type, who participated in a multicenter, double-blind study comparing olanzapine to haloperidol. Methods: Patients with schizoaffective disorder bipolar type, characterized as currently manic, mixed, depressed, or euthymic, were assessed weekly for 6 weeks during treatment with either olanzapine or haloperidol. Manic symptoms were measured using the sum of six items of the BPRS, and depressive symptoms were assessed using the Montgomery-Asberg Depression Rating Scale. In addition, cognitive functioning was measured using the sum of seven items from the PANSS. Repeated measures analyses were performed using random coefficients regression of the serial measurement of manic, cognitive, and depressive symptoms. Results: A significant treatment difference was detected overall, indicating that olanzapine was significantly more effective than haloperidol in reducing symptoms of depression and improving patients' cognitive symptoms. The superiority of olanzapine over haloperidol in the reduction of manic symptoms did not reach statistical significance (P = .052). The greatest improvement in both manic and cognitive symptoms was seen in the olanzapine-treated 'currently manic' subgroup, and least improvement in the haloperidol-treated 'euthymic' subgroup. Depressive symptoms were most improved in the olanzapine-treated 'depressed' subgroup, and least improved in the corresponding haloperidol subgroup. Conclusions: Overall, olanzapine was superior to haloperidol with respect to thymoleptic effects in patients with schizoaffective disorder, bipolar type.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 133-140 |
| Number of pages | 8 |
| Journal | Journal of Affective Disorders |
| Volume | 67 |
| Issue number | 1-3 |
| DOIs | |
| State | Published - 2001 |
Fingerprint
Keywords
- Atypical antipsychotic
- Bipolar disorder
- Haloperidol
- Mania
- Olanzapine
- Schizoaffective disorder
ASJC Scopus subject areas
- Psychiatry and Mental health
- Behavioral Neuroscience
- Biological Psychiatry
- Neurology
- Psychology(all)
Cite this
Olanzapine versus haloperidol in schizoaffective disorder, bipolar type. / Tohen, Mauricio; Zhang, Fan; Keck, Paul E.; Feldman, Peter D.; Risser, Richard C.; Tran, Pierre V.; Breier, Alan.
In: Journal of Affective Disorders, Vol. 67, No. 1-3, 2001, p. 133-140.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Olanzapine versus haloperidol in schizoaffective disorder, bipolar type
AU - Tohen, Mauricio
AU - Zhang, Fan
AU - Keck, Paul E.
AU - Feldman, Peter D.
AU - Risser, Richard C.
AU - Tran, Pierre V.
AU - Breier, Alan
PY - 2001
Y1 - 2001
N2 - Background: The present analysis was performed on data from a subsample of patients with schizoaffective disorder, bipolar type, who participated in a multicenter, double-blind study comparing olanzapine to haloperidol. Methods: Patients with schizoaffective disorder bipolar type, characterized as currently manic, mixed, depressed, or euthymic, were assessed weekly for 6 weeks during treatment with either olanzapine or haloperidol. Manic symptoms were measured using the sum of six items of the BPRS, and depressive symptoms were assessed using the Montgomery-Asberg Depression Rating Scale. In addition, cognitive functioning was measured using the sum of seven items from the PANSS. Repeated measures analyses were performed using random coefficients regression of the serial measurement of manic, cognitive, and depressive symptoms. Results: A significant treatment difference was detected overall, indicating that olanzapine was significantly more effective than haloperidol in reducing symptoms of depression and improving patients' cognitive symptoms. The superiority of olanzapine over haloperidol in the reduction of manic symptoms did not reach statistical significance (P = .052). The greatest improvement in both manic and cognitive symptoms was seen in the olanzapine-treated 'currently manic' subgroup, and least improvement in the haloperidol-treated 'euthymic' subgroup. Depressive symptoms were most improved in the olanzapine-treated 'depressed' subgroup, and least improved in the corresponding haloperidol subgroup. Conclusions: Overall, olanzapine was superior to haloperidol with respect to thymoleptic effects in patients with schizoaffective disorder, bipolar type.
AB - Background: The present analysis was performed on data from a subsample of patients with schizoaffective disorder, bipolar type, who participated in a multicenter, double-blind study comparing olanzapine to haloperidol. Methods: Patients with schizoaffective disorder bipolar type, characterized as currently manic, mixed, depressed, or euthymic, were assessed weekly for 6 weeks during treatment with either olanzapine or haloperidol. Manic symptoms were measured using the sum of six items of the BPRS, and depressive symptoms were assessed using the Montgomery-Asberg Depression Rating Scale. In addition, cognitive functioning was measured using the sum of seven items from the PANSS. Repeated measures analyses were performed using random coefficients regression of the serial measurement of manic, cognitive, and depressive symptoms. Results: A significant treatment difference was detected overall, indicating that olanzapine was significantly more effective than haloperidol in reducing symptoms of depression and improving patients' cognitive symptoms. The superiority of olanzapine over haloperidol in the reduction of manic symptoms did not reach statistical significance (P = .052). The greatest improvement in both manic and cognitive symptoms was seen in the olanzapine-treated 'currently manic' subgroup, and least improvement in the haloperidol-treated 'euthymic' subgroup. Depressive symptoms were most improved in the olanzapine-treated 'depressed' subgroup, and least improved in the corresponding haloperidol subgroup. Conclusions: Overall, olanzapine was superior to haloperidol with respect to thymoleptic effects in patients with schizoaffective disorder, bipolar type.
KW - Atypical antipsychotic
KW - Bipolar disorder
KW - Haloperidol
KW - Mania
KW - Olanzapine
KW - Schizoaffective disorder
UR - http://www.scopus.com/inward/record.url?scp=0035721662&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035721662&partnerID=8YFLogxK
U2 - 10.1016/S0165-0327(00)00303-7
DO - 10.1016/S0165-0327(00)00303-7
M3 - Article
C2 - 11869760
AN - SCOPUS:0035721662
VL - 67
SP - 133
EP - 140
JO - Journal of Affective Disorders
JF - Journal of Affective Disorders
SN - 0165-0327
IS - 1-3
ER -